Old Web
English
Sign In
Acemap
>
Paper
>
Regorafenib in patients with refractory metastatic pancreatic cancer. An open-label phase II study (RESOUND)
Regorafenib in patients with refractory metastatic pancreatic cancer. An open-label phase II study (RESOUND)
2016
Silvia Bozzarelli
Lorenza Rimassa
Laura Giordano
S Sala
M.C. Tronconi
M Baretti
Nicola Personeni
T. Pressiani
Armando Santoro
Keywords:
Metastatic pancreatic cancer
Refractory
Medicine
Phases of clinical research
Regorafenib
Oncology
Internal medicine
open label
in patient
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
2
Citations
NaN
KQI
[]